{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-24-000099","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.949639+00:00","generated_at":"2026-05-31T09:50:12.187689+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senti Bio Q2 net loss $11.2M; doses first patients in Phase 1 AML trial","bullets":["Net loss of $11.2M ($2.45 per share) for Q2 2024; cash and equivalents $15.9M.","R&D expenses rose to $9.2M (vs $6.9M YoY) on increased manufacturing costs.","Phase 1 trial of SENTI-202 for AML now dosing; initial efficacy data expected by year-end 2024.","Received $8M CIRM grant to support SENTI-202 clinical development.","Regained Nasdaq minimum bid price compliance after 1-for-10 reverse stock split in July 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-24-000099","json":"https://secwatch.observer/filing/0001854270-24-000099.json","markdown":"https://secwatch.observer/filing/0001854270-24-000099.md","text":"https://secwatch.observer/filing/0001854270-24-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000099/0001854270-24-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000099/snti-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:50:12.187689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}